Form 4: Galectin Therapeutics Inc. Executive Khurram Jamil Reports Stock Option and Restricted Stock Unit Grant

Chief Medical Officer Khurram Jamil reports the acquisition of stock options and restricted stock units in Galectin Therapeutics Inc. on August 1, 2024.

Summary

• On August 1, 2024, Khurram Jamil, Chief Medical Officer of Galectin Therapeutics Inc., reported the acquisition of stock options and restricted stock units.
• The stock options grant consists of 100,000 options with an exercise price of $2.50, vesting in four equal installments between October 31, 2024, and July 31, 2025, and expiring on August 1, 2034.
• Jamil also acquired 10,000 restricted stock units (RSUs) that will vest 100% upon the public announcement of interim analysis data from the NAVIGATE clinical trial if the announcement is made on or before December 31, 2024; otherwise, they will expire unvested.
• The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and RSUs is a standard practice, and the vesting conditions are tied to a key clinical trial milestone, which could be a positive catalyst if successful.

Positives

• The grant of stock options and RSUs to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting of RSUs is tied to the announcement of interim data from the NAVIGATE clinical trial, incentivizing timely and successful data release.

Risks

• The RSUs will expire unvested if the NAVIGATE clinical trial interim data is not announced by December 31, 2024.

Future Outlook

The vesting of the RSUs is contingent on the announcement of interim data from the NAVIGATE clinical trial by December 31, 2024, which will be a key event to watch.

Industry Context

Grants of stock options and restricted stock units are common practices in the biotechnology industry to incentivize and retain key executives. The NAVIGATE trial is a key focus for Galectin Therapeutics, and the vesting of RSUs tied to its data release underscores its importance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to align management's interests with shareholder value.
• Companies like Madrigal Pharmaceuticals and Viking Therapeutics also utilize stock options and RSUs as part of their executive compensation plans.
• The vesting schedules and terms are generally comparable to industry norms, with vesting periods typically ranging from one to four years.

Stakeholder Impact

• Shareholders: Potential for increased value if the NAVIGATE clinical trial is successful and the executive is incentivized to perform well.
• Employees: The grant could have a positive impact on employee morale as it shows confidence in the company's future.

Next Steps

• Monitor the progress and announcement of interim data from the NAVIGATE clinical trial.
• Track the vesting of the stock options and RSUs.

Key Dates